≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Familial benign pemphigus (Hailey-Hailey disease)

Endpoint Browser PheWeb

Q17_FAMILIAL_BENIGN_PEMPHIGUS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q82.80
  • Cause of death: ICD-10 — Q82.80

2 out of 7 registries used, show all original rules.

84

4. Check minimum number of events

None

84

5. Include endpoints

None

84

6. Filter based on genotype QC (FinnGen only)

80

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 80 48 32
Unadjusted period prevalence (%) 0.02 0.02 0.01
Median age at first event (years) 53.42 51.82 55.81

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
84
Matched controls
840
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q82.80
ICD-10 Finland
Benign familial pemphigus [Hailey-Hailey]
+∞
120.9
84
*
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
28.2
56.1
53
48
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
13.3
27.8
33
39
Q82.88
ICD-10 Finland
Other specified congenital malformations of skin
+∞
26.4
24
*
D07CC01
ATC
betamethasone and antibiotics; topical
10.9
26.2
39
62
D05BB02
ATC
acitretin; oral
30.6
19.7
26
12
D07BA04
ATC
hydrocortisone and antiseptics; topical
9.8
17.5
24
33
E0000UV, ,
ATC
6.6
14.9
62
251
L30.9
ICD-10 Finland
Dermatitis, unspecified
5.6
13.1
35
95
D06AX01
ATC
fusidic acid; topical
6.7
11.3
21
40
Q82.81
ICD-10 Finland
Keratosis follicularis [Darier-White]
125.0
10.7
11
*
D07AD01
ATC
clobetasol; topical
5.2
10.6
28
74
E000002, ,
ATC
5.9
9.9
21
45
QBA25
NOMESCO Finland
Destruction of lesion of skin of trunk
25.2
9.7
13
6
WX402
NOMESCO Finland
General anaesthesia
4.5
9.6
32
101
D07BC01
ATC
betamethasone and antiseptics; topical
5.5
9.5
22
51
D07AC13
ATC
mometasone; topical
4.0
8.9
40
156
E000001, ,
ATC
4.3
8.8
31
101
D07AC01
ATC
betamethasone; topical
3.6
7.9
47
217
Q82.8
ICD-10 Finland
Other specified congenital malformations of skin
+∞
7.4
7
*
Q82.82
ICD-10 Finland
Inherited keratosis palmaris et plantaris
+∞
7.4
7
*
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.6
7.2
33
128
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
10.0
6.8
13
15
WX704
NOMESCO Finland
Intubation
7.4
6.5
15
24
ZXC07
NOMESCO Finland
Carbon dioxide laser
75.3
6.5
7
*
QBA40
NOMESCO Finland
Laser therapy or photocoagulation of skin of trunk
+∞
6.3
6
*
D07XB05
ATC
dexamethasone; topical
14.0
6.3
10
8
D02AE01
ATC
carbamide; topical
6.8
6.2
15
26
J01DA01
ATC
[U] cefalexin
3.7
6.1
66
417

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
1.0e+00
1.5e+00
7.6e-01
6.1e+00
1.6e+00
1.7e+00
1.6e+00
cases:77.38%
controls:54.88%
cases:71.43%
controls:36.55%
cases:14.29%
controls:7.26%
cases:77.38%
controls:0.71%
cases:32.14%
controls:8.81%
cases:77.11%
controls:38.82%
cases:90.91%
controls:66.40%
65
461
19
379
60
307
24
533
12
61
72
779
65
6
19
834
27
74
57
766
64
323
19
509
70
506
7
256
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.2e+00
3.4e+00
—
1.0e+50
—
4.2e+00
3.5e+00
cases:32.14%
controls:4.88%
cases:34.52%
controls:1.79%
—
—
cases:85.71%
controls:0.00%
—
—
cases:57.83%
controls:2.04%
cases:58.44%
controls:4.20%
27
41
57
799
29
15
55
825
—
72
0
12
840
—
48
17
35
815
45
32
32
730
combinations of corticosteroids
D07AB30 [21602118]
2.1e+00
3.1e+00
—
1.0e+50
—
3.1e+00
2.4e+00
cases:51.19%
controls:11.19%
cases:44.05%
controls:3.33%
—
—
cases:5.95%
controls:0.00%
—
—
cases:43.37%
controls:3.37%
cases:55.84%
controls:10.10%
43
94
41
746
37
28
47
812
—
5
0
79
840
—
36
28
47
804
43
77
34
685
combinations of corticosteroids
D07XB30 [21602188]
2.1e+00
3.1e+00
—
1.0e+50
—
3.1e+00
2.4e+00
cases:51.19%
controls:11.19%
cases:44.05%
controls:3.33%
—
—
cases:5.95%
controls:0.00%
—
—
cases:43.37%
controls:3.37%
cases:55.84%
controls:10.10%
43
94
41
746
37
28
47
812
—
5
0
79
840
—
36
28
47
804
43
77
34
685
hydrocortisone
S02BA01 [21605166]
2.1e+00
3.1e+00
—
—
1.0e+50
3.4e+00
2.2e+00
cases:33.33%
controls:5.83%
cases:27.38%
controls:1.67%
—
—
—
—
cases:9.52%
controls:0.00%
cases:24.10%
controls:1.08%
cases:36.36%
controls:5.91%
28
49
56
791
23
14
61
826
—
—
8
0
76
840
20
9
63
823
28
45
49
717
hydrocortisone
D07AA02 [21602102]
2.1e+00
3.1e+00
—
—
1.0e+50
3.2e+00
2.1e+00
cases:35.71%
controls:6.55%
cases:29.76%
controls:1.79%
—
—
—
—
cases:9.52%
controls:0.00%
cases:25.30%
controls:1.32%
cases:36.36%
controls:6.82%
30
55
54
785
25
15
59
825
—
—
8
0
76
840
21
11
62
821
28
52
49
710
hydrocortisone buteprate
D07AB11 [21602115]
2.1e+00
3.1e+00
—
—
1.0e+50
3.2e+00
2.1e+00
cases:35.71%
controls:6.55%
cases:29.76%
controls:1.79%
—
—
—
—
cases:9.52%
controls:0.00%
cases:25.30%
controls:1.32%
cases:36.36%
controls:6.82%
30
55
54
785
25
15
59
825
—
—
8
0
76
840
21
11
62
821
28
52
49
710
hydrocortisone aceponate
D07AC16 [21602135]
2.1e+00
3.1e+00
—
—
1.0e+50
3.2e+00
2.1e+00
cases:35.71%
controls:6.55%
cases:29.76%
controls:1.79%
—
—
—
—
cases:9.52%
controls:0.00%
cases:25.30%
controls:1.32%
cases:36.36%
controls:6.82%
30
55
54
785
25
15
59
825
—
—
8
0
76
840
21
11
62
821
28
52
49
710
hydrocortisone butyrate
D07AB02 [21602106]
2.1e+00
3.1e+00
—
—
1.0e+50
3.2e+00
2.1e+00
cases:35.71%
controls:6.55%
cases:29.76%
controls:1.79%
—
—
—
—
cases:9.52%
controls:0.00%
cases:25.30%
controls:1.32%
cases:36.36%
controls:6.82%
30
55
54
785
25
15
59
825
—
—
8
0
76
840
21
11
62
821
28
52
49
710
hydrocortisone
A07EA02 [21600654]
2.1e+00
3.1e+00
—
—
1.0e+50
3.1e+00
2.1e+00
cases:35.71%
controls:6.67%
cases:29.76%
controls:1.90%
—
—
—
—
cases:9.52%
controls:0.00%
cases:25.30%
controls:1.56%
cases:36.36%
controls:6.82%
30
56
54
784
25
16
59
824
—
—
8
0
76
840
21
13
62
819
28
52
49
710
hydrocortisone
C05AA01 [21601608]
2.1e+00
3.1e+00
—
—
1.0e+50
3.1e+00
2.1e+00
cases:35.71%
controls:6.67%
cases:29.76%
controls:1.90%
—
—
—
—
cases:9.52%
controls:0.00%
cases:25.30%
controls:1.56%
cases:36.36%
controls:6.82%
30
56
54
784
25
16
59
824
—
—
8
0
76
840
21
13
62
819
28
52
49
710
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
2.1e+00
2.5e+00
—
—
—
2.7e+00
2.3e+00
cases:21.43%
controls:3.33%
cases:14.29%
controls:1.31%
—
—
—
—
—
—
cases:15.66%
controls:1.20%
cases:23.38%
controls:2.89%
18
28
66
812
12
11
72
829
—
—
—
13
10
70
822
18
22
59
740
other preparations, combinations; ointment
C05AX03 [21601631]
2.1e+00
2.2e+00
—
—
—
2.7e+00
2.7e+00
cases:13.10%
controls:1.79%
cases:5.95%
controls:0.71%
—
—
—
—
—
—
cases:9.64%
controls:0.72%
cases:16.88%
controls:1.31%
11
15
73
825
5
6
79
834
—
—
—
8
6
75
826
13
10
64
752
Pharmacy visit
OMOP4822462 [581458]
3.9e-01
2.3e+00
3.8e-01
2.3e+00
9.2e-01
1.7e+00
5.9e-01
cases:95.24%
controls:93.10%
cases:97.62%
controls:80.24%
cases:46.43%
controls:37.26%
cases:17.86%
controls:2.14%
cases:60.71%
controls:38.21%
cases:95.18%
controls:78.73%
cases:97.40%
controls:95.41%
80
782
4
58
82
674
2
166
39
313
45
527
15
18
69
822
51
321
33
519
79
655
4
177
75
727
2
35
fusidic acid
D09AA02 [21602265]
1.7e+00
3.0e+00
—
—
—
—
2.3e+00
cases:10.71%
controls:2.14%
cases:10.71%
controls:0.60%
—
—
—
—
—
—
—
—
cases:15.58%
controls:1.84%
9
18
75
822
9
5
75
835
—
—
—
—
12
14
65
748
fusidic acid; ointment
D06AX01 [21602062]
1.7e+00
3.0e+00
—
—
—
—
2.3e+00
cases:10.71%
controls:2.14%
cases:10.71%
controls:0.60%
—
—
—
—
—
—
—
—
cases:15.58%
controls:1.84%
9
18
75
822
9
5
75
835
—
—
—
—
12
14
65
748
cefalexin; oral
J01DB01 [21602870]
9.3e-01
1.4e+00
2.3e+00
—
—
1.4e+00
9.9e-01
cases:47.62%
controls:26.43%
cases:29.76%
controls:9.88%
cases:10.71%
controls:1.19%
—
—
—
—
cases:27.71%
controls:9.01%
cases:53.25%
controls:29.79%
40
222
44
618
25
83
59
757
9
10
75
830
—
—
23
75
60
757
41
227
36
535
betamethasone
S02BA07 [21605169]
1.2e+00
2.4e+00
—
—
—
1.9e+00
1.5e+00
cases:13.10%
controls:4.29%
cases:19.05%
controls:2.14%
—
—
—
—
—
—
cases:10.84%
controls:1.80%
cases:18.18%
controls:4.86%
11
36
73
804
16
18
68
822
—
—
—
9
15
74
817
14
37
63
725
betamethasone
C05AA05 [21601610]
1.2e+00
2.4e+00
—
—
—
1.9e+00
1.5e+00
cases:13.10%
controls:4.29%
cases:19.05%
controls:2.14%
—
—
—
—
—
—
cases:10.84%
controls:1.80%
cases:18.18%
controls:4.86%
11
36
73
804
16
18
68
822
—
—
—
9
15
74
817
14
37
63
725
betamethasone
A07EA04 [21600656]
1.2e+00
2.4e+00
—
—
—
1.9e+00
1.5e+00
cases:13.10%
controls:4.29%
cases:19.05%
controls:2.14%
—
—
—
—
—
—
cases:10.84%
controls:1.80%
cases:18.18%
controls:4.86%
11
36
73
804
16
18
68
822
—
—
—
9
15
74
817
14
37
63
725
betamethasone
D07AC01 [21602120]
1.2e+00
2.4e+00
—
—
—
1.9e+00
1.5e+00
cases:13.10%
controls:4.29%
cases:19.05%
controls:2.14%
—
—
—
—
—
—
cases:10.84%
controls:1.80%
cases:18.18%
controls:4.86%
11
36
73
804
16
18
68
822
—
—
—
9
15
74
817
14
37
63
725
hydrocortisone
D07XA01 [21602180]
2.7e+00
—
—
—
1.0e+50
—
2.9e+00
cases:23.81%
controls:2.02%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:31.17%
controls:2.36%
20
17
64
823
—
—
—
7
0
77
840
—
24
18
53
744
chlorhexidine, combinations
D08AC52 [21602208]
2.7e+00
—
—
—
1.0e+50
—
2.9e+00
cases:23.81%
controls:2.02%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:31.17%
controls:2.36%
20
17
64
823
—
—
—
7
0
77
840
—
24
18
53
744
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
2.7e+00
—
—
—
1.0e+50
—
2.9e+00
cases:23.81%
controls:2.02%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:31.17%
controls:2.36%
20
17
64
823
—
—
—
7
0
77
840
—
24
18
53
744
hydrocortisone and antiseptics
D07BA04 [21602146]
2.7e+00
—
—
—
1.0e+50
—
2.9e+00
cases:23.81%
controls:2.02%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:31.17%
controls:2.36%
20
17
64
823
—
—
—
7
0
77
840
—
24
18
53
744
chlorhexidine
D09AA12 [21602275]
2.7e+00
—
—
—
1.0e+50
—
2.9e+00
cases:23.81%
controls:2.02%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:31.17%
controls:2.36%
20
17
64
823
—
—
—
7
0
77
840
—
24
18
53
744
triamcinolone and antiseptics
D07BB03 [21602150]
2.7e+00
—
—
—
1.0e+50
—
2.9e+00
cases:23.81%
controls:2.02%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:31.17%
controls:2.36%
20
17
64
823
—
—
—
7
0
77
840
—
24
18
53
744
chlorhexidine
S03AA04 [21605193]
2.7e+00
—
—
—
1.0e+50
—
2.9e+00
cases:23.81%
controls:2.02%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:31.17%
controls:2.36%
20
17
64
823
—
—
—
7
0
77
840
—
24
18
53
744
chlorhexidine
S02AA09 [21605155]
2.7e+00
—
—
—
1.0e+50
—
2.9e+00
cases:23.81%
controls:2.02%
—
—
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:31.17%
controls:2.36%
20
17
64
823
—
—
—
7
0
77
840
—
24
18
53
744
hydrocortisone; local oral
A01AC03 [21600036]
2.3e+00
—
—
—
—
—
3.1e+00
cases:15.48%
controls:1.79%
—
—
—
—
—
—
—
—
—
—
cases:23.38%
controls:1.31%
13
15
71
825
—
—
—
—
—
18
10
59
752
hydrocortisone; oral, parenteral
H02AB09 [21602737]
2.2e+00
—
—
—
—
—
3.0e+00
cases:15.48%
controls:1.90%
—
—
—
—
—
—
—
—
—
—
cases:23.38%
controls:1.44%
13
16
71
824
—
—
—
—
—
18
11
59
751
hydrocortisone and antiinfectives
S03CA04 [21605208]
2.7e+00
—
—
—
—
—
2.1e+00
cases:14.29%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
cases:11.69%
controls:1.57%
12
9
72
831
—
—
—
—
—
9
12
68
750
hydrocortisone and antiinfectives
S02CA03 [21605175]
2.7e+00
—
—
—
—
—
2.1e+00
cases:14.29%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
cases:11.69%
controls:1.57%
12
9
72
831
—
—
—
—
—
9
12
68
750
antibiotics in combination with corticosteroids
D01AA20 [21601918]
2.2e+00
—
—
—
—
—
2.1e+00
cases:10.71%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
cases:11.69%
controls:1.57%
9
11
75
829
—
—
—
—
—
9
12
68
750
clobetasol
D07AD01 [21602141]
2.0e+00
—
—
—
—
—
2.3e+00
cases:9.52%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:12.99%
controls:1.44%
8
12
76
828
—
—
—
—
—
10
11
67
751
antibiotics in combination with other drugs
S01AA20 [21603571]
1.0e+00
1.7e+00
—
—
—
2.0e+00
1.5e+00
cases:15.48%
controls:6.31%
cases:8.33%
controls:1.67%
—
—
—
—
—
—
cases:10.84%
controls:1.56%
cases:20.78%
controls:5.51%
13
53
71
787
7
14
77
826
—
—
—
9
13
74
819
16
42
61
720
Case Management Agency
251B00000X [38004193]
-2.0e-01
1.8e-01
4.5e-01
3.3e+00
8.0e-01
2.0e-01
1.0e-01
cases:33.33%
controls:37.98%
cases:34.52%
controls:30.48%
cases:16.67%
controls:11.31%
cases:16.67%
controls:0.71%
cases:23.81%
controls:12.26%
cases:38.55%
controls:34.01%
cases:58.44%
controls:55.91%
28
319
56
521
29
256
55
584
14
95
70
745
14
6
70
834
20
103
64
737
32
283
51
549
45
426
32
336
mometasone
D07AC13 [21602132]
1.3e+00
1.2e+00
—
—
—
—
1.8e+00
cases:14.29%
controls:4.29%
cases:5.95%
controls:1.79%
—
—
—
—
—
—
—
—
cases:20.78%
controls:4.33%
12
36
72
804
5
15
79
825
—
—
—
—
16
33
61
729
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
2.5e+00
1.0e+50
—
1.0e+50
—
—
—
cases:7.14%
controls:0.60%
cases:5.95%
controls:0.00%
—
—
cases:14.29%
controls:0.00%
—
—
—
—
—
—
6
5
78
835
5
0
79
840
—
12
0
72
840
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
2.5e+00
—
—
—
—
—
—
cases:7.14%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
78
835
—
—
—
—
—
—
hydrocortisone and antiinfectives
S01CA03 [21603654]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.69%
controls:1.18%
—
—
—
—
—
—
9
9
68
753
tetracycline; oral, parenteral
J01AA07 [21602805]
—
—
—
—
—
2.4e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.60%
cases:7.79%
controls:1.71%
—
—
—
—
—
5
5
78
827
6
13
71
749
hydroxyzine; oral, parenteral
N05BB01 [21604590]
2.4e+00
—
—
—
—
—
-1.0e+50
cases:5.95%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
5
5
79
835
—
—
—
—
—
0
8
77
754
dexamethasone
S01BA01 [21603618]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.92%
—
—
—
—
—
—
6
7
71
755
dexamethasone
S03BA01 [21605201]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.92%
—
—
—
—
—
—
6
7
71
755
tacrolimus
D11AH01 [21602338]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:1.18%
—
—
—
—
—
—
7
9
70
753
pregabalin; oral
N02BF02 [955152]
1.9e+00
—
—
—
—
—
—
cases:8.33%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
77
829
—
—
—
—
—
—
Supplier / Service Provider
OMOP5117446 [33004]
-1.7e+00
—
—
—
—
—
3.4e+00
cases:7.14%
controls:28.69%
—
—
—
—
—
—
—
—
—
—
cases:16.88%
controls:0.66%
6
241
78
599
—
—
—
—
—
13
5
64
757
Dermatitis, unspecified
L30.9 [45572271]
—
—
1.0e+50
—
—
—
1.7e+00
—
—
—
—
cases:5.95%
controls:0.00%
—
—
—
—
—
—
cases:11.69%
controls:2.36%
—
—
5
0
79
840
—
—
—
9
18
68
744
Physical Medicine And Rehabilitation
25 [38004468]
6.0e-01
1.7e+00
—
—
—
—
1.0e-01
cases:8.33%
controls:4.76%
cases:9.52%
controls:1.90%
—
—
—
—
—
—
—
—
cases:6.49%
controls:5.91%
7
40
77
800
8
16
76
824
—
—
—
—
5
45
72
717
More than one and less than three hours
ZXE10 [2001311401]
1.4e+00
—
—
—
—
—
8.7e-01
cases:13.10%
controls:3.57%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:3.41%
11
30
73
810
—
—
—
—
—
6
26
71
736
prednisolone
A07EA01 [21600653]
4.4e-01
1.1e+00
—
—
—
8.8e-01
1.2e+00
cases:10.71%
controls:7.14%
cases:9.52%
controls:3.45%
—
—
—
—
—
—
cases:7.23%
controls:3.13%
cases:22.08%
controls:8.01%
9
60
75
780
8
29
76
811
—
—
—
6
26
77
806
17
61
60
701
prednisolone; oral, parenteral
H02AB06 [21602734]
4.6e-01
1.1e+00
—
—
—
8.8e-01
1.2e+00
cases:10.71%
controls:7.02%
cases:9.52%
controls:3.45%
—
—
—
—
—
—
cases:7.23%
controls:3.13%
cases:22.08%
controls:8.01%
9
59
75
781
8
29
76
811
—
—
—
6
26
77
806
17
61
60
701
Orthopedic Surgery
20 [38004465]
1.1e+00
1.3e+00
—
—
—
3.5e-01
1.5e-01
cases:21.43%
controls:8.21%
cases:10.71%
controls:3.21%
—
—
—
—
—
—
cases:6.02%
controls:4.33%
cases:14.29%
controls:12.60%
18
69
66
771
9
27
75
813
—
—
—
5
36
78
796
11
96
66
666
Inpatient Hospital
21 [8717]
6.0e-01
7.0e-01
—
—
—
1.1e+00
3.7e-01
cases:46.43%
controls:32.14%
cases:16.67%
controls:9.05%
—
—
—
—
—
—
cases:22.89%
controls:9.25%
cases:33.77%
controls:25.98%
39
270
45
570
14
76
70
764
—
—
—
19
77
64
755
26
198
51
564
Dizziness and giddiness
R42 [45568132]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
glimepiride; oral
A10BB12 [21600761]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
6
84
834
—
—
—
0
5
83
827
—
Dorsalgia
M54 [45553203]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
83
826
—
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.4e-01
—
—
—
—
—
1.1e+00
cases:11.90%
controls:6.07%
—
—
—
—
—
—
—
—
—
—
cases:14.29%
controls:5.12%
10
51
74
789
—
—
—
—
—
11
39
66
723
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
84
834
—
—
—
—
—
—
Other specified pulpit
K04.08 [2000502703]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
0
8
77
754
Gastro-oesophageal reflux disease
K21 [45586708]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
0
12
84
828
—
—
—
—
0
7
83
825
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
—
7.7e-01
—
—
—
—
—
—
—
cases:5.95%
controls:2.86%
—
—
—
—
—
—
—
—
—
—
—
5
24
79
816
—
—
—
—
—
EKG study
11524-6 [3013512]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
—
0
12
84
828
—
—
—
—
—
glucagon; nasal, parenteral
H04AA01 [21602778]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
0
6
84
834
—
—
—
—
—
0
5
77
757
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
—
—
—
—
—
—
-1.2e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.39%
controls:10.50%
—
—
—
—
—
—
8
80
69
682
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
7
77
755
Trisomy 18 risk [Likelihood] in Fetus
43994-3 [3047352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
tinzaparin; parenteral
B01AB10 [21600981]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
omeprazole; oral, parenteral
A02BC01 [21600096]
—
1.3e+00
—
—
—
—
—
—
—
cases:5.95%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
—
5
14
79
826
—
—
—
—
—
long-acting sulfonamides - combinations
J01ED20 [21602959]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
0
5
84
835
—
—
—
0
7
83
825
—
Choriogonadotropin [Units/volume] in Serum or Plasma
19080-1 [3018171]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
84
834
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.2e-01
4.3e-01
6.4e-01
—
1.1e+00
3.1e-01
4.2e-02
cases:22.62%
controls:17.50%
cases:22.62%
controls:15.95%
cases:5.95%
controls:3.21%
—
—
cases:10.71%
controls:3.81%
cases:21.69%
controls:16.83%
cases:29.87%
controls:29.00%
19
147
65
693
19
134
65
706
5
27
79
813
—
9
32
75
808
18
140
65
692
23
221
54
541
Dysthymia
F34.1 [45586238]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
83
826
—
bisoprolol and thiazides
C07BB07 [21601714]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.92%
—
—
—
—
—
0
5
83
827
0
7
77
755
Monocytes [#/volume] in Blood
26484-6 [3001604]
—
6.6e-01
—
—
—
4.7e-01
5.8e-01
—
—
cases:7.14%
controls:3.81%
—
—
—
—
—
—
cases:6.02%
controls:3.85%
cases:12.99%
controls:7.74%
—
6
32
78
808
—
—
—
5
32
78
800
10
59
67
703
bisoprolol; oral
C07AB07 [21601689]
2.5e-01
2.8e-01
—
—
—
1.6e-01
2.0e-01
cases:11.90%
controls:9.52%
cases:9.52%
controls:7.38%
—
—
—
—
—
—
cases:9.64%
controls:8.29%
cases:15.58%
controls:13.12%
10
80
74
760
8
62
76
778
—
—
—
8
69
75
763
12
100
65
662
HLA-B27 [Presence]
4821-5 [3008898]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Sequelae of cerebral infarction
I69.3 [45533476]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
fluoxetine; oral
N06AB03 [21604711]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
7
77
755
fluticasone furoate
R03BA09 [45893496]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
0
15
83
817
—
Atrial fibrillation and flutter
I48 [45596206]
—
—
—
—
—
—
6.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:3.67%
—
—
—
—
—
—
5
28
72
734
Sneezing/nasal congestion
R07 [2002000888]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
—
General symptom/complaint other
A29 [2002000163]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
0
5
84
835
—
—
—
—
0
5
77
757
X-ray examination of the lungs in one projection
GD1PA [2001303645]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
83
827
—
dextromethorphan; oral
R05DA09 [21603404]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
0
5
84
835
—
—
—
0
7
83
825
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
4.3e-01
—
—
—
—
8.4e-01
5.3e-02
cases:17.86%
controls:12.38%
—
—
—
—
—
—
—
—
cases:7.23%
controls:3.25%
cases:11.69%
controls:11.15%
15
104
69
736
—
—
—
—
6
27
77
805
9
85
68
677
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
6.0e-01
1.3e+00
—
—
—
1.3e+00
-1.5e-01
cases:8.33%
controls:4.76%
cases:8.33%
controls:2.50%
—
—
—
—
—
—
cases:7.23%
controls:2.16%
cases:7.79%
controls:8.92%
7
40
77
800
7
21
77
819
—
—
—
6
18
77
814
6
68
71
694
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
allopurinol; oral, parenteral
M04AA01 [21604131]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.90%
cases:0.00%
controls:1.31%
—
—
—
—
—
—
cases:0.00%
controls:1.44%
cases:0.00%
controls:2.62%
0
16
84
824
0
11
84
829
—
—
—
0
12
83
820
0
20
77
742
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
—
—
—
—
—
-2.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:8.01%
—
—
—
—
—
—
5
61
72
701
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
—
0
11
84
829
—
—
—
—
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
—
—
—
—
—
—
6.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:4.33%
—
—
—
—
—
—
6
33
71
729
Other hypothyroidism
E03 [45581337]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
0
8
77
754
Outcome of delivery
Z37 [45581024]
-2.6e-01
—
—
—
—
—
—
cases:5.95%
controls:7.62%
—
—
—
—
—
—
—
—
—
—
—
—
5
64
79
776
—
—
—
—
—
—
Seborrhoeic keratosis
L82 [45548208]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
84
830
—
—
—
—
—
—
Limited function/disability (L)
L28 [2002000647]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Migraine without aura [common migraine]
G43.0 [45600784]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Clinic/Center
261Q00000X [38004207]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
—
Primary total prosthetic replacement of knee joint without patellar part
NGB20 [2001308094]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
—
—
—
0
11
77
751
Pulmonary Disease
29 [38004472]
1.6e-01
1.2e+00
—
—
-1.0e+50
—
2.1e-01
cases:5.95%
controls:5.12%
cases:5.95%
controls:1.79%
—
—
—
—
cases:0.00%
controls:0.60%
—
—
cases:9.09%
controls:7.48%
5
43
79
797
5
15
79
825
—
—
0
5
84
835
—
7
57
70
705
Low back pain
M54.5 [45553207]
—
1.7e+00
—
—
—
—
—
—
—
cases:5.95%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
5
10
79
830
—
—
—
—
—
chlorphenamine, combinations
R06AB54 [21603468]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
0
9
83
823
—
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
3.2e-01
4.4e-01
6.4e-01
—
1.1e+00
3.2e-01
4.2e-02
cases:22.62%
controls:17.50%
cases:22.62%
controls:15.83%
cases:5.95%
controls:3.21%
—
—
cases:10.71%
controls:3.81%
cases:21.69%
controls:16.71%
cases:29.87%
controls:29.00%
19
147
65
693
19
133
65
707
5
27
79
813
—
9
32
75
808
18
139
65
693
23
221
54
541
Pain/tenderness of skin
S01 [2002000966]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Extensive health check-up of expecting family
SPAT1197 [2001700298]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.26%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.84%
0
19
84
821
—
—
—
—
—
0
14
77
748
Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection
49891-5 [3029511]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
0
8
77
754
Dyspnoea
R06.0 [45558449]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
83
827
—
Nephrology
39 [38004479]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
0
6
84
834
—
—
—
0
7
83
825
—
almotriptan; oral
N02CC05 [21604380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma
32166-1 [3008714]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
0
5
84
835
—
—
—
—
0
6
77
756
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Dentistry
C5 [903277]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
83
826
—
Extensive body CT
JN4BD [2001310899]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
7
84
833
0
5
84
835
—
—
—
—
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
—
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
6
84
834
—
—
—
—
—
Lower uterine segment caesarean section
MCA10 [2001306959]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
0
8
77
754
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
acetylsalicylic acid; oral
B01AC06 [21600991]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
83
827
—
Celiac disease serology panel - Serum
94494-2 [36660697]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
0
6
84
834
—
—
—
—
0
5
83
827
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
0
8
83
824
—
Tinea unguium
B35.1 [45590850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
Hematology
82 [38004501]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
83
827
—
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
0
6
84
834
—
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
—
6.3e-01
—
—
—
4.4e-01
5.2e-01
—
—
cases:7.14%
controls:3.93%
—
—
—
—
—
—
cases:6.02%
controls:3.97%
cases:12.99%
controls:8.14%
—
6
33
78
807
—
—
—
5
33
78
799
10
62
67
700
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
5
84
835
—
—
—
—
0
6
83
826
—
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
84
830
—
—
—
—
—
—
Psychiatry
26 [38004469]
6.9e-01
—
—
—
—
—
—
cases:9.52%
controls:5.00%
—
—
—
—
—
—
—
—
—
—
—
—
8
42
76
798
—
—
—
—
—
—
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
84
834
—
—
—
—
—
—
Split tooth for reasons other than trauma
K03.82 [2000502700]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
—
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:1.44%
—
—
—
0
8
84
832
—
—
0
5
84
835
0
12
83
820
—
Cocaine [Presence] in Urine
3397-7 [3016879]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
0
10
84
830
—
—
—
—
—
0
6
77
756
Fracture of rib
S22.3 [45573285]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
felodipine; oral
C08CA02 [21601748]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
84
833
—
0
5
84
835
—
—
azelaic acid; ointment
D10AX03 [21602314]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
84
834
—
—
—
—
—
—
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Photocoagulation of retina
CKC12 [2001301394]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
0
5
84
835
—
—
—
—
—
0
8
77
754
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
0
7
84
833
—
—
—
0
10
83
822
—
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
84
825
—
—
—
—
—
—
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
—
7.3e-01
8.7e-01
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:3.61%
cases:11.69%
controls:5.25%
—
—
—
—
—
6
30
77
802
9
40
68
722
mometasone; nasal
R01AD09 [21605051]
1.1e-01
—
—
—
—
—
1.1e-01
cases:8.33%
controls:7.50%
—
—
—
—
—
—
—
—
—
—
cases:10.39%
controls:9.45%
7
63
77
777
—
—
—
—
—
8
72
69
690
Risk factor cardiovascular disease
K22 [2002000551]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
—
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
0
8
84
832
—
—
—
0
9
83
823
—
calcipotriol; ointment
D05AX02 [21602039]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
—
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
0
12
84
828
—
—
—
—
0
5
83
827
—
Other senile cataract
H25.8 [45605644]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
0
10
77
752
losartan and diuretics
C09DA01 [21601834]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
—
0
11
84
829
—
—
—
0
12
83
820
—
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
7
77
755
nystatin; oral
A07AA02 [21600604]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
tolfenamic acid; oral, rectal
M01AG02 [21603988]
1.3e+00
—
—
—
—
-1.0e+50
—
cases:7.14%
controls:2.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
6
18
78
822
—
—
—
—
0
10
83
822
—
amitriptyline; oral, parenteral
N06AA09 [21604696]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:2.76%
—
—
—
—
—
—
6
21
71
741
Diabetes, insulin-treated
103 [2001600103]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
22
84
818
—
—
—
—
—
—
Curettage of cervix and body of uterus
LCA13 [2001306553]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
84
830
—
—
—
—
—
—
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
T81.0 [45599741]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
—
Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma
76348-2 [46235831]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
0
5
84
835
—
—
—
—
0
6
77
756
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.07%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
9
84
831
0
5
84
835
—
—
—
—
—
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
0
5
84
835
—
—
—
—
0
10
77
752
Other complicated root filling
SGB30 [2001310390]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
0
5
84
835
—
—
—
—
—
0
9
77
753
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
fluticasone, combinations
R01AD58 [43534837]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.39%
controls:3.81%
—
—
—
—
—
—
8
29
69
733
Base excess in Venous blood by calculation
1927-3 [3002032]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
7
77
755
COVID-19, virus not identified
U07.2 [45756094]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
0
5
84
835
—
—
—
0
8
83
824
—
metronidazole and furazolidone
P01AB51 [45893518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
84
832
—
—
—
—
—
—
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
0
5
84
835
—
—
—
—
—
0
8
77
754
Bacteria identified in Urine by Culture
630-4 [3026008]
1.0e+00
2.0e+00
—
—
—
2.2e+00
8.5e-01
cases:5.95%
controls:2.26%
cases:5.95%
controls:0.83%
—
—
—
—
—
—
cases:6.02%
controls:0.72%
cases:6.49%
controls:2.89%
5
19
79
821
5
7
79
833
—
—
—
5
6
78
826
5
22
72
740
ramipril; oral
C09AA05 [21601789]
8.0e-01
—
—
—
—
6.9e-01
4.3e-01
cases:7.14%
controls:3.33%
—
—
—
—
—
—
—
—
cases:6.02%
controls:3.13%
cases:6.49%
controls:4.33%
6
28
78
812
—
—
—
—
5
26
78
806
5
33
72
729
mirabegron; oral
G04BD12 [43534790]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
tranexamic acid; oral, parenteral
B02AA02 [21601036]
1.3e+00
—
—
—
—
—
—
cases:5.95%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
—
—
5
14
79
826
—
—
—
—
—
—
perphenazine; oral, parenteral, rectal
N05AB03 [21604502]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
-1.5e-01
—
—
—
—
-1.0e+50
—
cases:8.33%
controls:9.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
7
80
77
760
—
—
—
—
0
16
83
816
—
Sleep apnoea
G47.3 [45562094]
—
-1.0e+50
—
—
—
—
8.7e-01
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
cases:7.79%
controls:3.41%
—
0
9
84
831
—
—
—
—
6
26
71
736
opium derivatives and expectorants
R05FA02 [21603439]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
0
5
84
835
—
—
—
0
7
83
825
—
nepafenac
S01BC10 [21603648]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
83
826
—
Tissue transglutaminase IgG Ab [Units/volume] in Serum
32998-7 [3046870]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
vortioxetine; oral
N06AX26 [44819158]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
0
5
84
835
0
5
84
835
—
—
—
0
5
83
827
—
oxycodone; oral, parenteral
N02AA05 [21604260]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
83
826
—
Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
32046-5 [3021584]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.95%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
8
84
832
0
5
84
835
—
—
—
—
—
Bicipital tendinitis
M75.2 [45557984]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Missed abortion
O02.1 [45567878]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
—
insulin (beef); parenteral
A10AD02 [21600730]
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:2.14%
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
0
18
84
822
—
0
10
84
830
—
—
—
—
quetiapine; oral
N05AH04 [21604544]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
cases:0.00%
controls:1.68%
—
—
—
—
0
6
84
834
—
—
0
14
83
818
—
Telephone prescription or other care instructions
WZB00 [2001310884]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
5
83
827
—
calcium (different salts in combination); oral
A12AA20 [21600872]
—
6.5e-01
—
—
—
4.1e-01
-4.7e-02
—
—
cases:8.33%
controls:4.52%
—
—
—
—
—
—
cases:6.02%
controls:4.09%
cases:7.79%
controls:8.14%
—
7
38
77
802
—
—
—
5
34
78
798
6
62
71
700
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
0
5
84
835
—
—
—
0
7
83
825
—
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
doxycycline; oral, parenteral
J01AA02 [21602800]
5.4e-01
6.0e-01
-1.0e+50
—
—
—
-2.2e-02
cases:32.14%
controls:21.67%
cases:8.33%
controls:4.76%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:18.18%
controls:18.50%
27
182
57
658
7
40
77
800
0
6
84
834
—
—
—
14
141
63
621
Impacted cerumen
H61.2 [45562307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Cystitis, unspecified
N30.9 [45606488]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
0
5
84
835
—
—
—
—
—
0
5
77
757
olanzapine; oral, parenteral
N05AH03 [21604543]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
0
5
84
835
—
—
—
—
—
0
10
77
752
MCH [Entitic mass]
28539-5 [3035941]
3.2e-01
4.4e-01
6.4e-01
—
1.1e+00
3.3e-01
4.2e-02
cases:22.62%
controls:17.50%
cases:22.62%
controls:15.83%
cases:5.95%
controls:3.21%
—
—
cases:10.71%
controls:3.81%
cases:21.69%
controls:16.59%
cases:29.87%
controls:29.00%
19
147
65
693
19
133
65
707
5
27
79
813
—
9
32
75
808
18
138
65
694
23
221
54
541
Lump/swelling localized
S04 [2002000969]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Trisomy 21 risk [Likelihood] in Fetus
43995-0 [3043238]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
0
5
84
835
—
—
—
—
—
0
6
77
756
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.0e-01
3.7e-01
—
—
—
2.7e-01
1.6e-01
cases:17.86%
controls:13.93%
cases:14.29%
controls:10.36%
—
—
—
—
—
—
cases:15.66%
controls:12.38%
cases:25.97%
controls:22.97%
15
117
69
723
12
87
72
753
—
—
—
13
103
70
729
20
175
57
587
Ear pain/earache
H01 [2002000475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
84
832
—
—
—
—
—
—
Infectious Disease
44 [38004484]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.31%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:1.05%
0
11
84
829
—
—
—
—
0
6
83
826
0
8
77
754
prednisone; oral
H02AB07 [21602735]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
0
11
84
829
—
—
—
—
—
0
11
77
751
vilanterol and fluticasone furoate
R03AK10 [43534841]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
6.2e-01
1.3e+00
—
—
—
1.2e+00
-1.2e-01
cases:8.33%
controls:4.64%
cases:8.33%
controls:2.38%
—
—
—
—
—
—
cases:7.23%
controls:2.28%
cases:7.79%
controls:8.66%
7
39
77
801
7
20
77
820
—
—
—
6
19
77
813
6
66
71
696
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
0
8
84
832
—
—
—
—
—
0
7
77
755
Left sided colitis
K51.5 [45533604]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Cardiology
6 [38004451]
3.8e-01
—
—
—
—
—
-5.3e-02
cases:5.95%
controls:4.17%
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:6.82%
5
35
79
805
—
—
—
—
—
5
52
72
710
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
1.1e-01
7.4e-01
—
—
—
1.4e+00
3.7e-01
cases:8.33%
controls:7.50%
cases:9.52%
controls:4.76%
—
—
—
—
—
—
cases:10.84%
controls:2.88%
cases:14.29%
controls:10.37%
7
63
77
777
8
40
76
800
—
—
—
9
24
74
808
11
79
66
683
Weakness/tiredness general
A04 [2002000145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
7
77
755
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.6e-02
1.7e-01
—
—
—
2.4e-01
4.0e-01
cases:9.52%
controls:9.05%
cases:7.14%
controls:6.07%
—
—
—
—
—
—
cases:7.23%
controls:5.77%
cases:18.18%
controls:12.99%
8
76
76
764
6
51
78
789
—
—
—
6
48
77
784
14
99
63
663
Endocrine, nutritional and metabolic diseases complicating pregnancy, childbirth and the puerperium
O99.2 [45534321]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
dexamethasone
C05AA09 [21601613]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
Concussion
S06.0 [45582805]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Oral Surgery
19 [38004464]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
84
832
—
—
—
—
—
—
Osmolality of Urine
2695-5 [3026782]
—
-1.0e+50
—
—
—
—
7.6e-01
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
cases:6.49%
controls:3.15%
—
0
10
84
830
—
—
—
—
5
24
72
738
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
2.8e-01
1.6e-01
—
—
—
4.9e-01
3.9e-01
cases:19.05%
controls:15.12%
cases:11.90%
controls:10.36%
—
—
—
—
—
—
cases:14.46%
controls:9.38%
cases:23.38%
controls:17.06%
16
127
68
713
10
87
74
753
—
—
—
12
78
71
754
18
130
59
632
Health maint/preventive medicine
A98 [2002000231]
-3.4e-01
-7.7e-02
—
—
—
1.4e-01
4.3e-01
cases:13.10%
controls:17.50%
cases:11.90%
controls:12.74%
—
—
—
—
—
—
cases:16.87%
controls:15.02%
cases:38.96%
controls:29.40%
11
147
73
693
10
107
74
733
—
—
—
14
125
69
707
30
224
47
538
amlodipine; oral
C08CA01 [21601747]
6.4e-01
2.6e-01
-1.0e+50
—
—
5.7e-01
2.5e-01
cases:9.52%
controls:5.24%
cases:5.95%
controls:4.64%
cases:0.00%
controls:1.31%
—
—
—
—
cases:7.23%
controls:4.21%
cases:9.09%
controls:7.22%
8
44
76
796
5
39
79
801
0
11
84
829
—
—
6
35
77
797
7
55
70
707
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
—
—
—
—
—
—
5.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:4.72%
—
—
—
—
—
—
6
36
71
726
Tooth plaque
K03.66 [2000502691]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
0
5
84
835
—
—
—
—
—
0
6
77
756
Oncology Clinic/Center
261QX0200X [38004268]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
—
—
—
—
—
—
-1.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:7.22%
—
—
—
—
—
—
5
55
72
707
dapagliflozin; oral
A10BK01 [1123890]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Memory disturbance
P20 [2002000816]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
0
5
84
835
—
—
—
—
0
7
77
755
Knee X-ray examination without contrast
NG1AA [2001308049]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
6
84
834
—
—
—
—
—
Bilateral
ZXA10 [2001311348]
—
—
—
—
—
—
8.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:2.76%
—
—
—
—
—
—
5
21
72
741
Obstetric epidural analgesia
WX307 [2001310797]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Infiltration anesthesia
WX110 [2001310767]
9.4e-02
—
—
—
-1.0e+50
8.0e-01
6.1e-01
cases:11.90%
controls:10.95%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:9.64%
controls:4.57%
cases:22.08%
controls:13.39%
10
92
74
748
—
—
—
0
5
84
835
8
38
75
794
17
102
60
660
naproxcinod
M01AE18 [40254094]
5.7e-01
8.4e-01
—
—
—
—
2.0e-02
cases:20.24%
controls:12.50%
cases:7.14%
controls:3.21%
—
—
—
—
—
—
—
—
cases:9.09%
controls:8.92%
17
105
67
735
6
27
78
813
—
—
—
—
7
68
70
694
bupropion; oral
N06AX12 [21604741]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
0
6
84
834
—
—
—
—
—
0
5
77
757
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
8.7e-02
3.3e-01
-1.0e+50
—
—
4.0e-01
1.9e-01
cases:21.43%
controls:20.00%
cases:14.29%
controls:10.71%
cases:0.00%
controls:1.31%
—
—
—
—
cases:16.87%
controls:12.02%
cases:31.17%
controls:27.30%
18
168
66
672
12
90
72
750
0
11
84
829
—
—
14
100
69
732
24
208
53
554
Nonorganic insomnia
F51.0 [45552492]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
84
829
—
—
—
—
—
—
Acute tubulo-interstitial nephritis
N10 [45543856]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
84
830
—
—
—
—
—
—
Amphetamines [Presence] in Urine
3349-8 [3027944]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
84
830
—
—
—
—
—
—
cough suppressants and mucolytics
R05FB01 [21603441]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
0
5
84
835
—
—
—
0
7
83
825
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
1.4e+00
—
—
—
—
-1.0e+50
—
cases:5.95%
controls:1.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
5
13
79
827
—
—
—
—
0
5
83
827
—
Surface analgesia on skin or mucosa
WX105 [2001310765]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
0
6
84
834
—
—
—
—
—
0
6
77
756
Fear of hypertension
K25 [2002000553]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Primary gonarthrosis, bilateral
M17.0 [45562648]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
83
826
—
metronidazole; oral, rectal
P01AB01 [21604857]
5.8e-01
-1.0e+50
—
—
—
-1.0e+50
6.9e-01
cases:10.71%
controls:6.31%
cases:0.00%
controls:1.67%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:10.39%
controls:5.51%
9
53
75
787
0
14
84
826
—
—
—
0
8
83
824
8
42
69
720
insulin detemir; parenteral
A10AE05 [21600740]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:2.62%
cases:0.00%
controls:1.79%
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:2.04%
—
—
0
22
84
818
0
15
84
825
—
—
0
6
84
834
0
17
83
815
—
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
0
9
84
831
—
—
—
—
—
0
5
77
757
insulin lispro; parenteral
A10AC04 [21600726]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.67%
cases:0.00%
controls:1.19%
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
0
14
84
826
0
10
84
830
—
—
0
5
84
835
—
—
Examination and observation for other specified reasons
Z04.8 [45552063]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.84%
0
11
84
829
—
—
—
—
—
0
14
77
748
Simple examination of mouth
SAA01 [2001310274]
8.2e-02
5.8e-01
-1.0e+50
—
—
4.8e-01
2.9e-01
cases:11.90%
controls:11.07%
cases:10.71%
controls:6.31%
cases:0.00%
controls:0.71%
—
—
—
—
cases:8.43%
controls:5.41%
cases:23.38%
controls:18.64%
10
93
74
747
9
53
75
787
0
6
84
834
—
—
7
45
76
787
18
142
59
620
Nausea and vomiting
R11 [45539317]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.55%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
13
84
827
0
7
84
833
—
—
—
0
6
83
826
—
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.55%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
0
13
84
827
0
6
84
834
—
—
—
—
—
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
Syncope and collapse
R55 [45568141]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
84
830
—
—
—
—
—
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
1.1e-01
—
-1.0e+50
—
-1.0e+50
—
2.3e-01
cases:7.14%
controls:6.43%
—
—
cases:0.00%
controls:0.95%
—
—
cases:0.00%
controls:1.19%
—
—
cases:10.39%
controls:8.40%
6
54
78
786
—
0
8
84
832
—
0
10
84
830
—
8
64
69
698
Office Visit
OMOP4822458 [581477]
9.1e-01
—
—
—
—
9.1e-01
4.2e-01
cases:13.10%
controls:5.71%
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.52%
cases:10.39%
controls:7.09%
11
48
73
792
—
—
—
—
5
21
78
811
8
54
69
708
celecoxib; oral
M01AH01 [21603992]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
6
83
826
—
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
—
—
—
—
—
—
2.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:6.17%
—
—
—
—
—
—
6
47
71
715
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
1.0e+00
—
—
—
—
—
7.8e-02
cases:8.33%
controls:3.21%
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:6.04%
7
27
77
813
—
—
—
—
—
5
46
72
716
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
—
—
—
—
—
7.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:3.94%
—
—
—
—
—
—
6
30
71
732
Supervision of other high-risk pregnancies
Z35.8 [45552076]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
Acute pharyngitis, unspecified
J02.9 [45538472]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: occasional
SMOKING-1-1-2 [2002330117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
—
Assistance to normal delivery
MAX99 [2001306918]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
0
10
77
752
finasteride; oral
G04CB01 [21602675]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
7
84
833
0
5
84
835
—
—
—
—
—
Derangement of meniscus due to old tear or injury
M23.2 [45591779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
timolol
S01ED01 [21603699]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
6
84
834
0
5
84
835
—
—
—
—
—
insulin aspart; parenteral
A10AD05 [21600733]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
0
7
84
833
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
84
824
—
—
—
—
—
—
Specific gravity of Urine by Test strip
5811-5 [3000330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
0
8
77
754
triamcinolone; nasal
R01AD11 [21605052]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
84
830
—
—
—
—
—
—
Extensive abdominal CT
JN3BD [2001305556]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
—
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
—
—
—
—
-1.0e+50
—
2.8e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
cases:6.49%
controls:4.99%
—
—
—
—
0
6
84
834
—
5
38
72
724
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
10
83
822
—
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
5
77
757
First trimester maternal screen panel - Serum or Plasma
48798-3 [3050129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
tiotropium bromide; inhalant
R03BB04 [21603296]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
0
7
84
833
—
—
—
—
0
5
83
827
—
Short blood count panel - Blood
55429-5 [40758558]
—
—
—
—
—
—
7.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:3.67%
—
—
—
—
—
—
6
28
71
734
Other investigative procedure of eye
XCW99 [2001301491]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
0
10
77
752
Standard cardiac ultrasound examination
FM1AE [2001303278]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
0
9
84
831
—
—
—
—
—
0
11
77
751
Body mass index
60621009 [4245997]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.69%
controls:0.00%
—
—
—
—
—
—
9
0
68
762
Urgent procedure
ZXD05 [2001311386]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
84
834
—
—
—
—
—
—
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
—
carvedilol; oral
C07AG02 [21601700]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.31%
cases:0.00%
controls:1.07%
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:1.44%
cases:0.00%
controls:2.23%
0
11
84
829
0
9
84
831
—
—
0
5
84
835
0
12
83
820
0
17
77
745
Opiates [Presence] in Urine
3879-4 [3027008]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
84
830
—
—
—
—
—
—
Colonoscopy Study observation
28023-0 [3022145]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.43%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
12
84
828
0
5
84
835
—
—
—
—
—
Osteoarthrosis of knee
L90 [2002000709]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
6
77
756
drospirenone and ethinylestradiol
G03AA12 [21602485]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.95%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
0
8
84
832
0
5
84
835
—
—
—
—
0
5
77
757
General Surgery
2 [38004447]
1.8e-01
2.6e-01
—
—
—
1.6e-01
3.2e-01
cases:23.81%
controls:20.71%
cases:8.33%
controls:6.55%
—
—
—
—
—
—
cases:6.02%
controls:5.17%
cases:24.68%
controls:19.16%
20
174
64
666
7
55
77
785
—
—
—
5
43
78
789
19
146
58
616
glibenclamide; oral
A10BB01 [21600750]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.55%
cases:0.00%
controls:1.19%
—
—
—
—
—
—
cases:0.00%
controls:1.08%
cases:0.00%
controls:1.18%
0
13
84
827
0
10
84
830
—
—
—
0
9
83
823
0
9
77
753
Administration of medicine
SPAT1254 [2001700355]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
Laceration/cut
S18 [2002000983]
1.0e+00
—
—
—
—
—
7.3e-01
cases:9.52%
controls:3.69%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:4.59%
8
31
76
809
—
—
—
—
—
7
35
70
727
valsartan; oral
C09CA03 [21601826]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.23%
—
—
—
—
—
—
0
17
77
745
Tissue Pathology biopsy report
66121-5 [40768804]
5.4e-01
—
-1.0e+50
—
—
—
1.1e+00
cases:7.14%
controls:4.29%
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:9.09%
controls:3.15%
6
36
78
804
—
0
5
84
835
—
—
—
7
24
70
738
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
1.3e-01
0.0e+00
-1.0e+50
—
—
-1.4e-01
2.7e-02
cases:11.90%
controls:10.60%
cases:5.95%
controls:5.95%
cases:0.00%
controls:1.31%
—
—
—
—
cases:6.02%
controls:6.85%
cases:20.78%
controls:20.34%
10
89
74
751
5
50
79
790
0
11
84
829
—
—
5
57
78
775
16
155
61
607
Other and unspecified convulsions
R56.8 [45602033]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
84
835
—
—
—
—
—
—
s-atenolol; oral
C07AB11 [21601693]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:1.05%
0
10
84
830
—
—
—
—
0
8
83
824
0
8
77
754
folic acid; oral, parenteral
B03BB01 [21601129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
9
77
753
dexamethasone and antiinfectives
S01CA01 [21603652]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
7
84
833
—
—
—
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
5.0e-01
2.4e-01
—
—
1.2e+00
4.9e-01
3.2e-01
cases:20.24%
controls:13.33%
cases:14.29%
controls:11.55%
—
—
—
—
cases:7.14%
controls:2.26%
cases:18.07%
controls:11.90%
cases:28.57%
controls:22.44%
17
112
67
728
12
97
72
743
—
—
6
19
78
821
15
99
68
733
22
171
55
591

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
20
31
8.12
8.87
1.5
1.3
—
—
—
0
0
24
84
3.60
5.96
2.4
1.4
—
—
—
0
0
10
13
8.56
5.01
1.0
1.2
—
—
—
0
0
53
366
2.21
3.03
6.7
6.7
26.41
27.30
%
0.23
48
347
37
228
2.11
2.77
5.1
7.6
—
—
—
0
0
47
326
2.00
2.48
2.3
2.0
1.41
1.35
mmol/l
0.16
42
273
12
47
2.81
2.39
1.1
1.4
—
32.00
—
0
5
50
358
1.98
2.37
6.8
6.5
3.05
2.81
%
0.34
45
336
26
151
2.05
2.21
6.0
3.2
17.29
80.09
ng/l
1.08
21
112
53
394
1.94
2.18
7.1
6.8
0.05
0.04
e9/l
0.94
45
344
48
346
1.90
2.16
3.7
2.7
—
—
estimate
—
0
0
54
406
1.92
2.12
7.1
6.8
0.21
0.19
e9/l
0.26
45
364
53
397
1.91
2.10
7.2
6.8
1.82
1.82
e9/l
0.03
47
359
52
392
1.86
1.97
7.2
6.8
0.58
0.58
e9/l
0.01
43
344
35
240
1.79
1.76
6.4
6.4
—
—
—
0
0
8
31
2.74
1.71
3.0
1.8
—
—
—
0
0
28
181
1.82
1.70
1.2
1.3
1.90
2.70
u/ml
—
6
44
34
241
1.69
1.48
4.5
3.3
0.00
0.01
estimate
—
10
68
13
67
2.11
1.48
1.2
1.1
—
—
—
0
0
42
315
1.67
1.47
4.7
3.9
0.00
0.01
estimate
0.49
11
72
29
198
1.71
1.44
5.8
4.7
—
—
—
0
0
16
91
1.94
1.41
6.8
6.4
7.42
7.42
ph
—
9
59
39
293
1.62
1.33
2.9
4.4
40.05
24.61
ng/l
0.27
25
208
16
93
1.89
1.32
1.4
1.2
—
—
—
0
0
8
36
2.35
1.28
2.7
10.0
24.31
24.82
mmol/l
—
8
36
51
412
1.61
1.27
4.9
3.8
0.00
0.00
estimate
-0.00
12
88
18
111
1.79
1.25
2.4
2.1
—
—
—
0
0
50
406
1.57
1.18
4.9
3.8
0.00
0.00
estimate
-0.00
12
85
41
319
1.56
1.17
4.1
3.6
6.24
6.15
ph
0.26
27
191
16
98
1.78
1.13
1.1
1.3
—
—
—
0
0
42
331
1.54
1.12
12.7
12.4
0.00
0.00
e9/l
0.80
34
277
25
176
1.60
1.08
4.4
4.1
1.02
1.02
kg/l
0.24
17
116
11
61
1.92
1.04
4.7
3.5
—
—
—
0
0
50
414
1.51
1.03
4.9
3.9
0.00
0.00
estimate
-0.00
12
79
42
338
1.49
0.98
2.5
2.0
91.07
97.36
pmol/l
0.40
22
170
44
361
1.46
0.91
17.0
13.1
1.23
1.20
inr
0.16
39
294
30
231
1.46
0.85
4.2
2.8
—
—
—
0
0
51
440
1.40
0.75
9.9
11.7
4.19
4.14
e9/l
0.05
44
391
24
181
1.46
0.74
5.5
3.9
86.63
90.74
%
0.28
24
181
5
26
1.98
0.72
1.2
1.7
80.40
44.92
nmol/l
—
5
26
22
165
1.45
0.70
1.3
1.4
12.75
6.52
u/ml
—
6
65
10
62
1.70
0.68
1.4
1.4
—
—
—
0
0
33
268
1.38
0.68
3.7
3.6
9.75
8.41
mg/mmol
0.06
20
161
10
63
1.67
0.65
4.6
7.4
—
—
—
0
0
42
357
1.35
0.64
2.1
2.7
81.67
102.42
ug/l
0.73
35
342
32
261
1.37
0.64
3.1
3.0
43.20
48.33
mg/l
0.06
21
166
8
51
1.63
0.62
6.8
3.5
—
—
—
0
0
5
30
1.71
0.62
1.0
1.3
1.21
1.21
g/l
—
5
30
5
30
1.71
0.62
1.0
1.3
0.24
0.23
g/l
—
5
30
30
244
1.36
0.60
3.6
4.1
7.39
7.40
ph
0.30
22
173
28
232
1.31
0.49
3.0
2.7
0.06
0.37
e6/l
2.52
22
171
69
728
0.71
0.49
5.7
5.2
6.02
5.84
mmol/l
0.91
62
681
39
340
1.27
0.46
5.6
6.3
1.19
1.21
mmol/l
1.50
39
316
22
179
1.31
0.43
1.5
1.4
56.25
27.17
iu/ml
—
8
67
5
32
1.60
0.43
1.0
1.1
—
—
—
0
0
9
66
1.41
0.40
1.3
2.8
9.09
4.86
ug/l
—
9
60
0
19
0.00
0.39
0.0
1.8
—
—
—
0
0
31
268
1.25
0.38
3.0
2.9
163.09
41.93
e6/l
0.37
25
209
27
312
0.80
0.37
3.0
3.4
—
—
—
0
0
15
118
1.33
0.36
1.3
1.8
—
—
—
0
0
6
42
1.46
0.36
1.7
2.5
22.40
24.04
mmol/l
—
6
42
13
100
1.35
0.36
1.5
1.4
—
—
—
0
0
6
44
1.39
0.35
1.7
3.2
7.42
7.42
ph
—
6
36
7
51
1.41
0.32
5.9
8.6
95.87
94.29
%
—
7
51
8
63
1.30
0.29
5.4
6.9
0.90
1.17
mmol/l
—
8
63
8
63
1.30
0.29
1.8
2.6
16.06
13.85
nmol/l
—
8
63
12
95
1.31
0.28
1.2
1.7
—
—
—
0
0
20
170
1.23
0.28
1.2
1.4
1.87
2.20
g/l
0.67
11
106
25
218
1.21
0.27
1.4
1.5
—
—
—
0
0
10
77
1.34
0.27
1.8
1.6
—
—
—
0
0
33
298
1.18
0.25
3.6
3.6
162.90
65.04
e6/l
0.37
26
214
34
309
1.17
0.23
2.2
2.1
—
—
—
0
0
76
740
1.28
0.22
21.9
16.5
23.44
21.79
mg/l
0.19
68
601
5
41
1.23
0.22
7.2
9.0
21.80
24.91
mmol/l
—
5
41
16
136
1.22
0.22
1.4
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
4.0
—
11.75
—
0
11
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
6
47
1.30
0.21
5.5
3.6
34.50
65.32
u/ml
—
6
47
21
185
1.18
0.20
6.8
6.5
—
—
—
0
0
6
52
1.17
0.19
1.2
1.3
—
—
—
0
0
26
235
1.15
0.19
3.0
2.4
—
—
—
0
0
5
67
0.73
0.17
1.4
1.8
—
—
—
0
0
9
77
1.19
0.16
1.3
1.5
—
—
—
0
0
5
46
1.09
0.10
1.0
1.2
—
—
—
0
0
5
48
1.04
0.09
3.2
1.9
—
—
—
0
0
6
58
1.04
0.08
2.2
3.7
—
—
—
0
0
24
227
1.08
0.07
6.2
4.0
0.00
0.00
estimate
-0.00
11
80
72
714
1.06
0.01
6.8
6.3
39.88
39.13
mmol/mol
0.32
66
676
74
741
0.99
0.00
6.8
5.4
4.61
4.60
mmol/l
0.02
69
699
71
709
1.01
0.00
5.4
4.5
1.29
1.27
mmol/l
0.15
63
660
6
66
0.90
0.00
1.5
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
39.20
—
0
8
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
9
94
0.95
-0.00
1.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
13.25
—
0
8
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
76
757
1.04
-0.00
26.5
18.2
4.00
3.96
mmol/l
0.82
76
744
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
32.00
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
27
270
1.00
-0.00
2.7
3.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
6.19
—
0
8
77
762
1.13
-0.00
18.1
14.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.3
—
0.41
—
0
8
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
31.13
—
0
9
0
9
0.00
-0.00
0.0
5.3
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: Q17_FAMILIAL_BENIGN_PEMPHIGUS – Familial benign pemphigus (Hailey-Hailey disease)

GWS hits: 14

This endpoint is excluded (different definition than used in FinnGen).